The EPO published patent application EP3715457A2 for Ionis Pharmaceuticals, Inc., covering antisense oligonucleotide compositions and methods for modulating Prekallikrein (PKK) expression. The patent is classified under C12N 15/113 (nucleic acid compounds) and A61K 31/7115 (therapeutic nucleotides). Inventors: FREIER, Susan M. and BUI, Huynh-hoa. The A2 publication includes a search report and designates all EU member states plus Switzerland, Norway, and other European countries.\n\nThis patent publication does not impose immediate compliance requirements. Competitors developing PKK-targeting antisense therapies should review the patent claims for freedom-to-operate considerations. No regulatory deadlines or penalties apply to this publication.